Publications by authors named "Clyde Markowitz"

Claim this Profile
B
Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment.
Laura R Naydovich, Jennifer L Orthmann-Murphy, Clyde E Markowitz

Neurotherapeutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating mood and cognition in people with multiple sclerosis: a prospective cross-sectional study protocol.
Elena C Cooper, Matthew K Schindler, Amit Bar-Or, Rachel B Brandstadter, Monica E Calkins, Clyde Markowitz

BMJ Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of insurance status on MRI phenotypes in MS.
Melissa Lynne Martin, Timothy Robert-Fitzgerald, Matthew K Schindler, Christopher Perrone, Guy Schultz, Clyde E Markowitz

Mult Scler Relat Disord· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Mood and Cognition in People with Multiple Sclerosis: A Prospective Study Protocol.
Elena C Cooper, Matthew K Schindler, Amit Bar-Or, Rachel B Brandstadter, Monica E Calkins, Clyde E Markowitz

medRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis.
Erica B Baller, Elizabeth M Sweeney, Matthew Cieslak, Timothy Robert-Fitzgerald, Sydney C Covitz, Clyde E Markowitz

Biol Psychiatry· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
Patricia K Coyle, Mark S Freedman, Bruce A Cohen, Bruce A C Cree, Clyde E Markowitz

Ann Clin Transl Neurol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy.
Stephanie Gandelman, Kerry A Lenzi, Clyde Markowitz, Joseph R Berger

Neurol Clin Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosis.
Kelly A Clark, Carly M O'Donnell, Mark A Elliott, Shahamat Tauhid, Blake E Dewey, Clyde Markowitz

J Neuroimaging· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis.
Simon Thebault, Stephanie Gandelman, Camryn Lane, Erin J Kim, Caitlin Pileggi, Clyde Markowitz

Neurol Neuroimmunol Neuroinflamm· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the relationship of white matter lesions to depression in multiple sclerosis.
Erica B Baller, Elizabeth M Sweeney, Matthew C Cieslak, Timothy Robert-Fitzgerald, Sydney C Covitz, Clyde E Markowitz

medRxiv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra.
Joseph R Berger, Clyde Markowitz, Peter A Merkel, Rachel A Kolster, Zissimos Mourelatos

J Neurol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability.
Jerry S Wolinsky, Natalie J Engmann, Jinglan Pei, Ashish Pradhan, Clyde Markowitz

Mult Scler J Exp Transl Clin· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncovering the association between fatigue and fatigability in multiple sclerosis using cognitive control.
Eli K Cehelyk, Denise Y Harvey, Meghan L Grubb, Rasha Jalel, Mohammad S El-Sibai, Clyde E Markowitz

Mult Scler Relat Disord· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciding on the Best Multiple Sclerosis Therapy: Tough Choices.
Joseph R Berger, Clyde Markowitz

JAMA Neurol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Edward J Fox, Clyde Markowitz, Angela Applebee, Xavier Montalban, Jerry S Wolinsky

Mult Scler· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limbic pathway lesions in patients with multiple sclerosis.
Neslin Sahin, Roger Selouan, Clyde E Markowitz, Elias R Melhem, Michel Bilello

Acta Radiol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-evaluating the treatment of acute optic neuritis.
Jeffrey L Bennett, Molly Nickerson, Fiona Costello, Robert C Sergott, Jonathan C Calkwood, Clyde E Markowitz

J Neurol Neurosurg Psychiatry· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis.
Salim Chahin, Deborah Miller, Reiko E Sakai, James A Wilson, Teresa Frohman, Clyde Markowitz

Mult Scler Relat Disord· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the treatment of neuromyelitis optica.
Jose Torres, Amy Pruitt, Laura Balcer, Steven Galetta, Clyde Markowitz

J Neurol Sci· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying and addressing unmet therapeutic needs in MS.
Clyde E Markowitz

J Clin Psychiatry· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching therapies in MS: what are the options?
Clyde E Markowitz

J Clin Psychiatry· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis.
Edward Fox, Barbara Green, Clyde Markowitz, Ronald Murray, Andrew D Goodman

BMC Neurol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, MerriKay Oleen-Burkey

BMC Neurol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel therapeutics in multiple sclerosis management: clinical applications.
Thomas Leist, Samuel F Hunter, Daniel Kantor, Clyde Markowitz

Am J Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple sclerosis update.
Clyde E Markowitz

Am J Manag Care· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis